Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis
ConclusionsEfpeglenatide significantly improves glycemic outcomes and promotes weight loss in individuals with diabetes. However, it is associated with moderate adverse effects related to the gastrointestinal system. Thus, further trials are warranted to comprehensively assess its safety and efficacy to derive a robust conclusion.Graphical abstract
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
More News: Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Gastroenterology | Heart | Study | Weight Loss